

## CURRICULUM VITAE

### Victoria L Robinson, PhD

Current Residence: Philadelphia, PA, USA

Mobile: +1-646-599-6534

Email: victoria.robinson@merck.com

### Education

PhD, Cancer Biology ▪ University of Chicago, Chicago, IL ▪ 2006

BS, Biology, *Magna cum laude* ▪ Fordham University, Bronx, NY ▪ 1999

### Current Position

Scientific Director Medical Affairs, Genitourinary Cancers ▪ Merck and Co., Inc, Kenilworth, NJ

### Professional Experience

Merck and Co., Inc, Kenilworth, NJ ▪ January 2014 – Present

- Oncology Scientific Affairs Strategy and Training Lead ▪ Jan 2017 – Jan 2019
- Research Scientific Director, Oncology ▪ Jan 2014 - Jan 2017

Eli Lilly and Company, Indianapolis, IN ▪ August 2012 – January 2014

- Oncology Medical Science Liaison

QD Healthcare, Stamford, CT ▪ July 2011 – August 2012

- Scientific Writer

### Research Experience

University of Chicago Medical Center, Chicago, IL ▪ 2007 – 2011

- Postdoctoral Fellow

University of Chicago Committee on Cancer Biology, Chicago, IL ▪ 2000 – 2006

- Graduate Student Researcher

Fordham University Biology Department, Bronx, NY ▪ 1997 – 1999

- Undergraduate Research Assistant

### Teaching Experience

City College of New York, New York, NY ▪ 2012

- Adjunct Professor, *Course title:* Biology 101

Pritzker School of Medicine, University of Chicago ▪ 2008 – 2011

- Teaching Assistant & Facilitator, *Course title:* Cellular and Molecular Biology

University of Chicago Medical Center ▪ 2004 – 2010

- Laboratory Research Advisor

University of Chicago, Division of Biological Sciences ▪ 2000 – 2001

- Teaching Assistant, *Course title:* Experimental Cancer Biology

### Selected Awards

William Harper Rainey Dissertation Fellowship, The University of Chicago ▪ 2005

Clare Boothe Luce Scholarship, Fordham University ▪ 1997

## **Professional Memberships**

Society for Immunotherapy of Cancer ▪ 2014 - present  
American Society of Clinical Oncology ▪ 2012 - present  
American Association for Cancer Research ▪ 2007 - present  
Bladder Cancer Advocacy Network Think Tank ▪ 2007-2011  
Society for Basic Urologic Research ▪ 2009-2011  
Sigma Xi ▪ 1999 - present

## **Scientific Publications**

### Peer-Reviewed Publications

- DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, and Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. *PLoS ONE* 2012; 7(5): e36669.
- Zhu H, Robinson VL, Dougherty U, Mustafi R, Fichera A, Joseph L, Bissonnette M. EGFR and c-myc suppress miR-143 and miR-145 in colonic tumorigenesis: roles of G1 cell cycle regulators. *Molecular Cancer Research* 2011; 9(7): 960-75.
- Otto K, Acharya S, Robinson VL. Stress-activated kinase pathway alteration is a frequent event in bladder cancer. *Urologic Oncology* 2011; Dec 9. [Epub ahead of print].
- Robinson VL, Shalhav O, Otto K, Kawai T, Gorospe M, Rinker-Schaeffer CW. *Map kinase kinase 4/c-jun NH2-terminal kinase kinase 1 (MKK4/JNKK1) protein expression is subject to translational regulation in prostate cancer cell lines.* *Molecular Cancer Research* 2008; 6(3): 501-508.
- Posadas EM, Al-Ahmadie H, Robinson VL, Otto K, Kasza K, Tretiakova M, Saddique J, Pienta K, Stadler WM, Rinker-Schaeffer CW, Salgia R. Fyn: a novel molecular target in prostate cancer. *BJU International* 2008;103(2): 171-177.
- Robinson VL, Hickson JA, Vander Griend DJ, Dubauskas Z, Rinker-Schaeffer CW. MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research. *Clinical Experimental Metastasis* 2003; 20(1): 25-30.
- Tan IP, Robinson VL, Risley MS. Gap junction-mediated dye coupling in rat seminiferous tubules. *Molecular Biology of the Cell* 1997; 8:(supplement): 418a: 2429.

### Reviews, Meeting Reports, Position Statements and Book Chapters

- DeGraff DJ, Robinson VL, Shah JB, Brandt WD, Sonpavde G, Kang Y, Liebert M, Wu XR, Taylor JA. Current preclinical models for the advancement of translational bladder cancer research. *Molecular Cancer Therapeutics* 2013; 12(2):121-130.
- Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y. Molecular detection of bladder cancer: the path to progress. *Urologic Oncology* 2010; 28(3): 334-337.
- Robinson VL and Cote R. What is cancer? The Guide to Living with Bladder Cancer. Bladder Cancer Advocacy Network.
- Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, White RD, Quale D, Lee CT. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. *Cancer* 2009; 115(18): 4096-4103.
- Robinson VL. Rethinking the central dogma: microRNAs are biologically relevant. *Urologic Oncology* 2009; 27(3): 304-306.

- Berger JC, Vander Griend DJ, Robinson VL, Hickson JA, Rinker-Schaeffer CW. Metastasis suppressor genes: from gene identification to protein function and regulation. *Cancer Biology and Therapy* 2005; 4(8): 805-812.
- Berger JC, Robinson VL, Hickson JA, Vander Griend DJ, Rinker-Schaeffer CW. Tumor-host interactions at the secondary site: MKK4, signal transduction and the stress response. Integration/ Interaction of Oncologic Growth, Meadows GG (ed) *Cancer Growth and Progression* 2005 (15) 437-448.
- Robinson VL, Kauffman EC, Solkoff MH, Rinker-Schaeffer CW. The Basic Biology of Metastasis. The Biology of Bone Metastasis. Keller ET and Chung LWK (eds) *Cancer Treatment Research* 2004 (118): 1-21.
- Kauffman EC, Robinson VL, Stadler WM, Solkoff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes in regulating cancer cell growth at the secondary site. *Journal of Urology* 2003; 169(3): 1122-1133.